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ABSTRACT
Objective: The objective of the study was to investigate the effect of leptin analog and salbutamol in obese asthmatic mice.
Methods: Obese asthmatic condition was induced by administration of hypercaloric diet for 8 weeks followed by ovalbumin-aluminum hydroxide. 
The animals were treated with leptin analog (0.4 mg/kg, i.p. for 14 days) and salbutamol (2 mg/kg, PO for 14 days). Biochemical parameters such as 
serum leptin, ghrelin, and tumor necrosis factor-α and physical parameters such as tidal volume and airflow rate were estimated to confirm the state 
of asthma and obesity, respectively.
Results: Elevated serum leptin and ghrelin were associated with leptin resistance in obese asthmatic mice. It was found that a significant increase in 
serum leptin level with animal treated with leptin analog and salbutamol when compared to animals treated with leptin analog alone. The result of 
respiratory parameters and serum parameters also improved with the combination of leptin analog and salbutamol. From our study, we found that 
salbutamol potentiates the effect of leptin analog in obese asthmatic condition.
Conclusion: Leptin analog and salbutamol are an alternative treatment approach to treat the obese asthmatic condition.
Keywords: Obesity, Asthma, Leptin analog, Salbutamol, Tumor necrosis factor alpha.
INTRODUCTION
Obesity is linked to the imbalance between energy expenditures [1]. It 
is due to excessive food intake with inactive lifestyle [2-4]. Obesity is 
one of the vital factors to worldwide for the burden of chronic sickness 
and disabilities. According to reports [5,6], over 1000 million adults 
worldwide are morbidly obese while of 300 million of them are clinically 
obese. Multiple factors contribute to the etiology are sedentary lifestyle, 
lack of physical activity and consumption of high energy-rich diet. The 
various study revealed that overall 20% men and 30% of females are 
obese worldwide [7]. The epidemic of obesity is becoming a universal 
problem, imposing considerable freight on the individual and society 
rising morbidity and mortality [8].
Asthma, a state of inflammation of airways involves different cells and 
cellular components such as eosinophils, somatic cells, lymphocytes, 
epithelial cells macrophages, and neutrophils; plays a crucial role in 
pathogenesis. These inflammatory cells cause repeated episodes of 
wheezing, dyspnea, chest tightness, coughing, and reversible airflow 
obstruction [9]. The inflammation results in elevated bronchial 
hyperresponsiveness to stimuli [10]. As of 2009, 300 million individuals 
globally were affected by asthma leading to approximately 250,000 
deaths per annum [11].
Epidemiologists, after a detailed study on the asthmatic spectrum, 
detected different asthmatic phenotypes (different identical 
characteristics of disease) and genotypes (different pathological origins of 
identical disease) [12,13]. One in every of phenotypes is obesity-induced 
asthma [14]. Obesity with asthma has been strongly associated with both 
genders [15]. Studies revealed that obesity could increase asthma severity 
and reduced the efficacy of standard asthma medications [16,17]. Various 
clinical studies showed that over 3 million adults whose body mass index 
higher than 25 were diagnosed with asthma [18].
It is reported that abnormal leptin and ghrelin levels are associated 
with obesity and asthma [19,20]. Both hormones regulate food intake 
through acting on neuropeptide–Y pathway [21]. Various studies 
showed that obesity is due to either leptin resistance or elevated serum 
leptin level [7,22,23]. Clinical studies also revealed a higher level of 
leptin in asthmatic patients [24]. Reports also revealed that the pro-
inflammatory effects of leptin are responsible for asthma in the obese 
population [25,26]. Thus, our investigation focuses on for effect of 
leptin analog with salbutamol in obese asthmatic mice.
At present, there are no treatment options available for the obese 
asthmatic condition. Even those treatments used for asthma and obesity 
have numerous side effects and costly. Therefore, there is a need for 
identification of effective treatment approach for asthma with obesity. 
In this study, we investigated the effect of leptin analog and salbutamol 
through hypercaloric diet-induced obesity in ovalbumin (OVA)-induced 
asthma in Swiss albino mice.
METHODS
Swiss albino mice of female sex weight in between 24±6 g were 
obtained from the central animal house of Faculty of Pharmacy, 
Dharmsinh Desai University, Nadiad. The animal studies were approved 
by the Institutional Ethics Committee (DDU/FOP/06/17), ratified 
by the purpose of control and supervision of experimental animals 
(CPCSEA) by Ministry of Environment and Forests, Government of 
India, New Delhi, India. Animals were naïve to drug treatment and 
experimentation at the beginning of all studies. Animals were kept 
individually in polypropylene cages in an environmentally controlled 
room of the animal house and maintained at a temperature of 25±2°C 
with a 12 h dark and light cycle. 10 days of acclimatization were 
provided to the animal. The animals were provided with water and 
food ad libitum. Mice were fed with laboratory pellet chow diet or 
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special high caloric diet according to the protocol. The composition of 
experimental diet (g/kg diet) was according to Soni et al. [15].
Experimental design
A total of 24 mice were used and divided into ten groups (n=6)
Group I (OB-AS)
(Obese asthmatic control mice) Animals were given with hypercaloric 
diet maintained for 8 weeks, and then, the induction phase of asthma was 
started. Mice were sensitized with OVA conjugated to aluminum hydroxide 
and challenged with saline to induce asthma. The induction with OVA was 
done on day 1–23 and challenge was for every 7th day for 3 weeks.
Group II (OB-AS-L)
(Leptin analog treated obese asthmatic mice) Animals were treated the 
same as mentioned in Group-I. Then, animals were treated with leptin 
analog (0.4 mg/kg, i.p. for 14 days) [27].
Group III (OB-AS-S)
(Salbutamol treated obese asthmatic mice) Animals were treated 
the same as mentioned in Group-I. Then, animals were treated with 
salbutamol (2 mg/kg, PO for 14 days) [28].
Group IV (OB-AS-L-S)
(Leptin analog and salbutamol treated obese asthmatic mice) Animals 
were treated the same as mentioned in Group-I. Then, animals were 
treated with leptin analog (0.4 mg/kg, i. p. for 14 days) with salbutamol 
(2 mg/kg, PO for 14 days) on the same day. There were 6 h intervals 
between leptin analog and salbutamol treatment for this group.
At the end of the experimental period, the animal was anesthetized with 
ketamine, following overnight fasting. Blood was drawn by the retro-
orbital method. Serum was separated by centrifugation at 4000 rpm 
(revolution per minute). Serum levels of leptin, ghrelin, and tumor 
necrosis factor- α (TNF-α) were measured using standard ELISA kits. 
The serum samples were stored at −70°C until analysis.
Measurement of respiratory parameters
Airflow rate was measured for the assessment of asthmatic condition. 
The measurement of respiratory parameters was performed as per 
Soni et al. [15].
Chemicals and diagnostic kits
Leptin analog (recombinant mouse leptin–cyt-31), Elisa kit for leptin 
(ELM-leptin-1 Mouse leptin Elisa 1*96 well), ghrelin (EIAM-GHR-1 
Mouse EIA 1*96 well), and TNF-α (ELM- TNF-α -1 Mouse TNF-alpha 
Elisa 1*96 well) were purchased from Everon life science, New Delhi, 
India.
Statistical analysis
Statistical evaluation of analytical data was done by one-way analysis of 
variance followed by Tukey’s test using statistical software GraphPad 
Prism 3.0. Data were expressed as mean ± standard error of the mean 
and significant was determined at p<0.05
RESULTS
Effect of leptin analog and salbutamol in the state of obese asthmatic 
condition was evaluated using respiratory and biochemical parameters 
such as serum leptin, ghrelin, and TNF-α. The results are represented by 
the graphical presentation.
Effect on airflow rate
Airflow rate was measured as respiratory parameters. It was observed 
that airflow rate was significantly increased in leptin analog treated 
an obese asthmatic animal (OB-AS-L), salbutamol treated an obese 
asthmatic animal (OB-AS-S), and leptin analog with salbutamol treated 
an obese asthmatic animal (OB-AS-L-S) when compared to an obese 
asthmatic animal (OB-AS) (Group I, *p<0.05). Airflow rate was also 
elevated in leptin analog with salbutamol treated obese asthmatic 
animals (OB-AS-L-S) when compared to leptin analog treated an obese 
asthmatic animal (OB-AS-L) (Group II, @ p<0.05) (Fig. 1).
Effect of serum leptin level
Fourteen days of administration of the drug treatment in obese asthmatic 
animals revealed a significant increase in serum leptin level in leptin 
analog treated obese asthmatic animal (OB-AS-L), and leptin analog 
with salbutamol treated an obese asthmatic animal (OB-AS-L-S) when 
compared to an obese asthmatic animal (OB-AS) (Group I, *p<0.05). No 
significant change observed in salbutamol treated an obese asthmatic 
animal (OB-AS-S). It was also found that elevated serum leptin level 
was observed in leptin analog with salbutamol treated obese asthmatic 
animals (OB-AS-L-S) when compared to leptin analog treated an obese 
asthmatic animal (OB-AS-L) (Group II, @ p<0.05) (Fig. 1).
Effect of serum ghrelin level
It was observed that serum ghrelin level was significantly decreased in 
leptin analog treated an obese asthmatic animal (OB-AS-L), salbutamol 
treated an obese asthmatic animal (OB-AS-S), and leptin analog with 
salbutamol treated an obese asthmatic animal (OB-AS-L-S) when 
compared to an obese asthmatic animal (OB-AS) (Group I, *p<0.05). 
It was also found that significant reduction in ghrelin level in leptin 
analog with salbutamol treated obese asthmatic animals (OB-AS-L-S) 
when compared to leptin analog treated an obese asthmatic animal 
(OB-AS-L) (Group II, p<0.05) (Fig. 1).
Effect of serum TNF-α level
TNF-α level was significantly decreased in leptin analog treated an obese 
asthmatic animal (OB-AS-L), salbutamol treated an obese asthmatic 
animal (OB-AS-S), and leptin analog with salbutamol treated an obese 
asthmatic animal (OB-AS-L-S) when compared to an obese asthmatic 
animal (OB-AS) (Group I, *p<0.05). It was also observed that significant 
reduction in TNF-α level in leptin analog with salbutamol treated obese 
asthmatic animals (OB-AS-L-S) when compared to leptin analog treated 
an obese asthmatic animal (OB-AS-L) (Group II, p<0.05) (Fig. 1).
DISCUSSION
Obesity is a nutritional disorder with inflammation and energy 
imbalance, occurring when calorie expenditure is less compared to high 
caloric food intake [29]. Obesity is mostly associated with abnormal 
physiological action of leptin [30,31]. Asthma symptoms such as dyspnea 
and wheezing appear as a result of an excess of thoracic and abdominal fat 
deposition [32]. Despite complex etiological factors for both conditions, 
leptin resistance was found to be one of the cause of asthmatic symptoms 
in obesity [33]. In the present study, we evaluated the effect of leptin 
analog with salbutamol to treat an obese asthmatic condition.
Hypercaloric diet has been used as a model of obesity induction in 
animals as its similarity with metabolic responses caused by obesity in 
humans [34]. It is reported that a hypercaloric diet induces significant 
body weight gain, adiposity, elevated serum triglycerides, and 
leptin [35]. Previously, it was reported that systemic leptin sensitivity 
was reduced after the 8th week of hypercaloric diet [36]. Hypercaloric 
diet consists of long-chain saturated fatty acids which are harmful 
lipids related to the accumulation of adipose content. These lipids bind 
to the toll-like receptor (TLR2 and TLR4) of microglia (cells that protect 
the hypothalamus) ultimately provokes the formation of inflammatory 
cytokines (TNF-α, interleukin [IL]-1β, and IL-6). These would 
consequently cause destroy the neurons for appetite homeostasis [37].
The ability of circulating adipokines, which augmented due to 
hypercaloric feeding, modify lung health is possible for the development 
of systemic inflammation. It was previously reported that the effect 
of hypocaloric diet-induced an alteration in respiratory airflow rate 
indicated breathing abnormality. This suggests that obesity may alter 
the condition of asthma or makes existing asthma more severe [38].
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Leptin, an adipokine hormone, inhibits food intake and increase energy 
expenditure by central action on hypothalamus [39,40] while ghrelin 
reported to be involved in increasing food intake [41]. Leptin effect is, 
therefore, antagonistic to the ghrelin effect. Previous studies reported 
that serum leptin level and ghrelin level were elevated in obesity [42]. 
These both hormones action is due to their role of regulating energy 
homeostasis through the changes in neuropeptide Y secretion [43].
Previously, it was reported that leptin resistance was accompanied by 
increased in serum ghrelin and serum leptin levels [20,42,33]. Clinical 
and preclinical studies suggested that obesity-induced raise in leptin 
level and leptin resistance would be responsible for worsening asthma 
symptoms [33].
Obesity is an inflammatory condition characterized by increased 
production of inflammatory cytokines [44]. Infiltration of macrophages 
in adipose tissue is a major cause for the release of TNF-α [45]. Consistent 
with previous finding, it is found that elevated TNF-α level was responsible 
factor for leptin resistance in asthma with obesity [46-47]. Furthermore, 
respiratory parameters were also improved with leptin analog (OB-
AS-L), salbutamol (OB-AS-S), and leptin analog with salbutamol (OB-AS-
L-S) treated obese asthmatic animals.
Salbutamol and orlistat are most preferable treatment approach for 
asthma and obesity, respectively. In this study, we investigated the effect 
of salbutamol with leptin analog in obesity-induced asthma in animals. 
For that, obese asthmatic animals were treated with leptin (OB-AS-L), 
salbutamol (OB-AS-S), and leptin with salbutamol (OB-AS-L-S). It 
was observed that serum leptin level significantly elevated in obese 
asthmatic animals treated with leptin analog (OB-AS-L) and treated 
with leptin analog with salbutamol (OB-AS-L-S) when compared to 
obese asthmatic animals (OB-AS). It was also observed that significantly 
raised serum leptin level in obese asthmatic animals treated with leptin 
analog with salbutamol (OB-AS-L-S) when compared to obese asthmatic 
animals treated with leptin analog (OB-AS-L). Thus, we may suggest that 
salbutamol produce synergistic action with leptin analog. No significant 
change was seen in obese asthmatic animals treated with salbutamol 
(OB-AS-S) when compared to obese asthmatic animals (OB-AS).
Present investigation revealed that there was an improvement in leptin 
resistance by increasing leptin and decreasing ghrelin which means 
decreased food intake with increased fat metabolism. It was observed 
that serum TNF-α level significantly reduced in obese asthmatic animals 
treated with leptin (OB-AS-L), salbutamol (OB-AS-S), and leptin analog 
with salbutamol (OB-AS-L-S) when compared to obese asthmatic 
animals (OB-AS).
Thus, investigation of the effect of leptin analog with salbutamol revealed 
that leptin analog with salbutamol was more effective in improving the 
state of obese asthmatic condition compared to alone leptin analog. 
Hence, we may suggest that leptin analog with salbutamol might be an 
effective treatment approach for the obese asthmatic condition.
CONCLUSION
From our study, we conclude that leptin analog with salbutamol 
would be treatment approach for this comorbid condition and could 
be improving the state of leptin resistance. However, further studies 
are needed to determine the clinical efficacy of leptin analogs with 
salbutamol inpatient of asthma associated obesity.
 Fig. 1: Effect of leptin analog and salbutamol on serum leptin, serum ghrelin, serum tumor necrosis factor- α, and airflow rate. *p<0.05 
when compared with OB-AS. @p<0.05 when compared with OB-AS-L
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